Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.07 and traded as high as $0.0894. Mateon Therapeutics shares last traded at $0.0894, with a volume of 24,773 shares traded.
Mateon Therapeutics Trading Down 0.4%
The firm’s 50 day simple moving average is $0.09 and its 200-day simple moving average is $0.07. The stock has a market capitalization of $8.07 million, a price-to-earnings ratio of -4.47 and a beta of 1.33.
About Mateon Therapeutics
Mateon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies that selectively target tumor tissue. The company’s platform leverages tumor-activated peptides designed to bind to the fibrin–fibronectin complexes uniquely present in solid tumors, with the goal of improving the therapeutic index of cytotoxic payloads while limiting off-target effects.
Its lead asset, MH1, is a peptide–drug conjugate in Phase I clinical trials for advanced solid tumors.
Recommended Stories
- Five stocks we like better than Mateon Therapeutics
- “Ominous day” coming to stocks…
- Punch these codes into your ordinary brokerage account
- The Crash Has Already Started (Most Just Don’t See It Yet)
- Trump just signed it
- A month before the crash
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
